Materials for cathepsin B enhancement and methods of use
AssigneeUniversity of North Carolina at Pembroke
InventorBen A. Bahr
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for treating a subject afflicted with a protein accumulation disease or TBI, comprising administering to the subject at least one compound that increases the level of active cathepsin B in cells of the subject, or a pharmaceutically acceptable salt or ester thereof, in an amount that is effective to treat the subject. The present invention also provides compositions for treating a subject afflicted with a protein accumulation disease or TBI.
Claims12
A method for treating a subject afflicted with Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, Mild Cognitive Impairment (MCI), or traumatic brain injury (TBI), the method comprising administering to the subject a phenylalanyl proline compound having the structure:
- or an analogue thereof, or a pharmaceutically acceptable salt or ester thereof;
- and
- further comprising administering to the subject one, two, three, or more of:
- i) N-carbobenzoxy-phenylalanyl-alanyl-diazomethylketone (PADK) or a PADK analogue, or a pharmaceutically acceptable salt or ester thereof;
- ii) N-carbobenzoxy-phenylalanyl-phenylalanyl-diazomethylketone (PPDK) or a pharmaceutically acceptable salt or ester thereof;
- iii) a PADK analogue having the structure:
- or a pharmaceutically acceptable salt or ester thereof;
- iv) a PADK analogue having the structure:
- or a pharmaceutically acceptable salt or ester thereof;
- v) a PADK analogue having the structure:
- or a pharmaceutically acceptable salt or ester thereof;
- or
- vi) a flavonoid,
- each in an amount that when administered together is effective to treat the subject.
A method for treating a subject afflicted with Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, Mild Cognitive Impairment (MCI), or traumatic brain injury (TBI), the method comprising administering to the subject an amount of a first compound and an amount of a second compound, wherein the first compound is N-benzyloxy-phenylalanyl-alanyl-diazomethylketone (PADK) or a PADK analogue, or a pharmaceutically acceptable salt or ester thereof, and wherein the second compound is a phenylalanyl proline compound having the structure:
- or an analogue thereof, or a pharmaceutically acceptable salt or ester thereof.
Dependencies are inferred from the claim text.